CFTR modulator can be safe, well-tolerated for younger children with common form of cystic fibrosis
Children ages two to five who have the most common form of cystic fibrosis (CF), caused by two copies of the F508 gene mutation, have not had any modulator treatments available to them until recently. A new study authored by researchers at Children s Hospital Colorado and published May 6, 2021, in
Lancet Respiratory Medicine shows that the CFTR modulator - lumacaftor/ivacaftor - can be safe and well-tolerated for this age range for up to 120 weeks, allowing younger children to begin proactive treatment of CF earlier in their lives.
E-Mail
IMAGE: Lead study author Jordana Hoppe, MD, a pediatric pulmonologist with Children s Hospital Colorado and assistant professor of pediatrics at the University of Colorado School of Medicine on the Anschutz Medical. view more
Credit: Children s Hospital Colorado
Children ages two to five who have the most common form of cystic fibrosis (CF), caused by two copies of the F508 gene mutation, have not had any modulator treatments available to them until recently. A new study authored by researchers at Children s Hospital Colorado and published May 6, 2021, in
Lancet Respiratory Medicine shows that the CFTR modulator - lumacaftor/ivacaftor - can be safe and well-tolerated for this age range for up to 120 weeks, allowing younger children to begin proactive treatment of CF earlier in their lives.
May 7, 2021
New Cornell-led research finds “little to no evidence” of a link between a person’s normal blood levels of vitamin D and risk of getting COVID-19, or the severity of an infection, in the most comprehensive study of its kind to date.
Multiple studies had suggested an association between vitamin D and COVID-19 risk, raising hopes that vitamin D supplements might help to prevent or minimize infections – speculation that has received widespread media attention and boosted consumer interest.
The new study, however, which analyzed a publicly available genomic data bank and 38 different COVID-19 studies worldwide – a total sample including nearly 1.4 million people – does not support those claims.
This illustration provided by the Centers for Disease Control and Prevention (CDC) in January 2020 shows the 2019 Novel Coronavirus (2019-nCoV). (CDC via AP, file photo)
Potentially big spreaders of the novel coronavirus can be the people least suspected of carrying the contagion, a recent study showed.
In a “social testing” project that started in October 2020, Tokyo’s Setagaya Ward office tested residents and workers at care facilities and related businesses for elderly and disabled people.
All 21,710 people tested as of April 27 showed no signs of COVID-19 symptoms, but 117 were in fact infected with the novel coronavirus.
Samples are analyzed under an amplification process to detect the virus. Larger quantities of the virus, which increase the risk of infecting others, require less amplification for detection.
Cain stepping down as VP, dean of Jacobs School buffalo.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from buffalo.edu Daily Mail and Mail on Sunday newspapers.